Table 2.
Remodelling echocardiographic, clinical, and biochemical patient parameters before and after sacubitril–valsartan treatment
| Before sacubitril–valsartan | After sacubitril–valsartan | P value | |
|---|---|---|---|
| Left ventricle end‐diastolic volume (mL) | 144 [119; 184] | 129 [107; 168] | 0.006 |
| Left ventricle end‐systolic volume (mL) | 93 [72; 128] | 73 [54; 104] | <0.001 |
| e/e´ | 13 [9; 18] | 11 [8; 15] | 0.053 |
| Global longitudinal strain (%) | −10.5 [−13; −7.3] | −12 [−15; −8] | 0.49 |
| Systolic blood pressure (mmHg) | 116 [106; 119] | 112 [100; 126] | 0.006 |
| Diastolic blood pressure (mmHg) | 70 [61; 76] | 68 [60; 72] | 0.30 |
| Heart rate (b.p.m.) | 74 [65; 81] | 68 [60; 75] | 0.01 |
| Creatinine (mg/dL) | 0.9 [0.7; 1.1] | 0.9 [0.7; 1.1] | 0.055 |
| Estimated glomerular filtration rate (mL/min/1.73 m2) | 76 [64; 90] | 70 [53; 88] | 0.02 |
| Potassium serum levels (mg/dL) | 4.5 [4.1; 4.8] | 4.5 [4.2; 4.8] | 0.50 |
| NT‐proBNP (pg/mL) | 1552 [692; 3624] | 776 [339; 1458] | 0.001 |
| NYHA functional class | 2.2 ± 0.6 | 1.6 ± 0.6 | <0.001 |
NT‐proBNP, N‐terminal pro‐B‐type natriuretic peptide; NYHA, New York Heart Association.